Press release
Pacira BioSciences, Inc. (NASDAQ: PCRX) Investor Alert: Deadline in Lawsuit on March 14, 2025
A Deadline is coming up on March 14, 2025 in the lawsuit for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX).
Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) have certain options and there are strict and short deadlines running. Deadline: March 14, 2025. Pacira BioSciences, Inc. (NASDAQ: PCRX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Pacira BioSciences, Inc. (NASDAQ: PCRX) common shares between August 2, 2023 to August 8, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 2, 2023 to August 8, 2024, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent.
Those who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pacira BioSciences, Inc. (NASDAQ: PCRX) Investor Alert: Deadline in Lawsuit on March 14, 2025 here
News-ID: 3903376 • Views: …
More Releases from Shareholders Foundation, Inc.
Ready Capital Corporation (NYSE: RC) Long Term Investor Investigation of potenti …
An investigation was announced for potential breaches of fiduciary duties by certain directors and officers of Ready Capital Corporation.
Investors who are current long term investors in Ready Capital Corporation (NYSE: RC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: RC stocks follows a lawsuit filed against Ready…
Investigation announced for Long-Term Investors in shares of Digimarc Corporatio …
An investigation was announced for current long-term investors in shares of Digimarc Corporation (NASDAQ: DMRC) concerning potential breaches of fiduciary duties by certain directors of Digimarc Corporation.
Investors who are current long term investors in Digimarc Corporation (NASDAQ: DMRC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: DMRC…
Ultra Clean Holdings, Inc. (NASDAQ: UCTT) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on May 23, 2025 in the lawsuit filed for certain investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) over alleged securities laws violations by Ultra Clean Holdings, Inc.
Investors who purchased shares of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) have certain options and there are strict and short deadlines running. Deadline: May 23, 2025. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) stockholders should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of West Pharmaceutical Se …
An investor, who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST), filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by West Pharmaceutical Services, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST) have certain options and for certain investors are short and strict deadlines running.…
More Releases for Pacira
Liposomes Drug Delivery Market Revenue,Facts,Statastics by 2026| Gilead Sciences …
Complete study of the global Liposomes Drug Delivery market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Liposomes Drug Delivery industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They…
Liposomes Drug Delivery Market Regional Forecast 2020 | Gilead Sciences, Novarti …
According to this study, over the next five years the Liposomes Drug Delivery market will register a 13.3% CAGR in terms of revenue, the global market size will reach $ 5397.1 million by 2025, from $ 3277.7 million in 2019.
Global Liposomes Drug Delivery Market 2020 by Marketandresearch.biz is an extensively researched and analyzed report on the market that will help market players to improve their business planning and ensure long-term…
Global Injectable Nanomedicines Market 2019 - Pacira Pharmaceuticals, Celgene Ph …
A new market research study by Apex Market Research has projected that Injectable Nanomedicines revenues will exceed $XX Billion by 2023 at a CAGR of XX%. Market statistics is published in Global Injectable Nanomedicines Market 2019-2026 report.
The Global Injectable Nanomedicines Market 2019-2026 report delivers comprehensive information about the Injectable Nanomedicines industry including valuable facts and figures, important aspects, and skilled opinions providing businesses with decisive information. The report covers global…
Global Liposomes Drug Delivery Market 2018 - CSPC, Novartis, Crucell, Pacira
Apex Market Research, recently published a detailed market research study focused on the "Liposomes Drug Delivery Market" across the global, regional and country level. The report provides 360° analysis of "Liposomes Drug Delivery Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Liposomes Drug Delivery industry, and estimates the future trend of…
Development Trends: HGH Biosimilars Market By Key Vendors: Gilead Sciences, Paci …
Qyresearchreports include new market research report HGH Biosimilars to its huge collection of research reports.
This report studies the global HGH Biosimilars market status and forecast, categorizes the global HGH Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa).
HGH Biosimilars…
Global Dupuytren Contracture Drug Market 2018 - MediWound Ltd, Pacira Pharmaceut …
Apex Market Reports, recently published a detailed market research study focused on the “Dupuytren Contracture Drug Market” across the global, regional and country level. The report provides 360° analysis of “Dupuytren Contracture Drug Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Dupuytren…
